Scalable AAV production in single use bioreactors

Monday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET

Sponsor

Scalable AAV production in single use bioreactors

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Production of high titer AAV at clinical scales remains a challenge for the gene therapy industry. Developers need to understand how to optimize, scale, and qualify their manufacturing process for AAV production under the tightest of time lines.

Due to high demand in the gene therapy space, effective solutions to address these challenges must be developed and implemented.

This month, Jon Zmuda (Director, Cell Biology, Thermo Fisher Scientific) will discuss how to meet the needs of this fast-moving industry. He will conduct a special Q&A to answer any questions on the demand webinars below and any other AAV production, purification, and process-related questions.

As a webinar attendee, you will learn about:

Enabling scalable, high-titer AAV production in single use bioreactors
How to optimize recovery and purity in downstream processing
Robust and efficient AAV production workflows

Watch: Complete system for AAV production for clinical production: Part 1 - Upstream

Watch: Optimizing vector production and purification to enhance scalable AAV manufacturing

Jon Zmuda

Director, Cell Biology Thermo Fisher Scientific

Jonathan Zmuda, Ph.D. is a Director of Cell Biology R&D within the Biosciences Division of Thermo Fisher Scientific located in Frederick, MD (USA). Within Cell Biology, Jon leads various teams that focus on developing new technologies for protein expression, viral vector production, transfection and classical cell culture. Dr. Zmuda received his Ph.D. in Cell Biology from the University of Maryland, College Park and his undergraduate degree from Dickinson College in Carlisle, PA.